See more : Antipa Minerals Limited (AZY.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Tyme Technologies, Inc. (TYME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tyme Technologies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Embellence Group AB (publ) (EMBELL.ST) Income Statement Analysis – Financial Results
- Tongda Group Holdings Limited (0698.HK) Income Statement Analysis – Financial Results
- Public Power Corporation S.A. (PUPOF) Income Statement Analysis – Financial Results
- Loyalty Founder Enterprise Co.,Ltd. (5465.TWO) Income Statement Analysis – Financial Results
- The Travelers Companies, Inc. (TRV) Income Statement Analysis – Financial Results
Tyme Technologies, Inc. (TYME)
About Tyme Technologies, Inc.
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.44M | 17.03M | 12.96M | 14.72M | 8.84M | 6.11M | 3.82M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.63M | 10.19M | 12.80M | 14.59M | 10.52M | 9.10M | 4.78M | 53.91K | 56.59K | 27.43K | 2.10K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.63M | 10.19M | 12.80M | 14.59M | 10.52M | 9.10M | 4.78M | 53.91K | 56.59K | 27.43K | 2.10K |
| Other Expenses | 2.44M | 0.00 | 0.00 | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.20K |
| Operating Expenses | 23.08M | 27.22M | 25.76M | 29.31M | 19.36M | 15.21M | 8.60M | 53.91K | 56.59K | 27.43K | -2.10K |
| Cost & Expenses | 23.08M | 27.22M | 25.76M | 29.31M | 19.36M | 15.21M | 8.60M | 53.91K | 56.59K | 27.43K | 2.10K |
| Interest Income | 0.00 | 22.08K | 229.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 70.24K | 97.13K | 114.24K | 0.00 | 0.00 | 0.00 | 3.50M | 76.56K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.96M | 5.18K | 5.18K | 8.42K | 4.30K | 4.28K | 4.29K | 76.56K | 0.00 | 0.00 | 0.00 |
| EBITDA | -23.56M | -27.22M | -25.76M | -31.78M | -19.36B | -15.21B | -8.60M | 22.65K | -56.59K | -27.43K | -2.10K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -25.51M | -27.22M | -25.76M | -31.78M | -19.36M | -15.21M | -8.60M | -53.91K | -56.59K | -27.43K | -2.10K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.89M | -1.76M | 3.76M | -1.21M | 19.34B | 15.19B | -3.13M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -23.63M | -28.98M | -22.00M | -32.98M | -18.97M | -15.21M | -11.73M | -53.91K | -56.59K | -27.43K | -2.10K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.96M | -1.66M | 3.87M | -1.21M | 390.39K | 0.00 | 376.26K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -21.67M | -28.98M | -22.00M | -32.98M | -18.97M | -15.21M | -11.73M | -53.91K | -56.59K | -27.43K | -2.10K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.13 | -0.22 | -0.19 | -0.32 | -0.21 | -0.18 | -0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.13 | -0.22 | -0.19 | -0.32 | -0.21 | -0.18 | -0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 172.21M | 134.25M | 114.53M | 102.35M | 90.57M | 84.45M | 77.85M | 52.00M | 12.00M | 47.60M | 39.00M |
| Weighted Avg Shares Out (Dil) | 172.21M | 134.25M | 114.53M | 102.35M | 90.57M | 84.45M | 77.85M | 52.00M | 12.00M | 47.60M | 39.00M |
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tyme Technologies, Inc. Merger
SHAREHOLDER ALERT: Weiss Law Investigates Syros Pharmaceuticals, Inc.
Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving
TYME Technologies Shares Surge On Merger Agreement With Syros Pharma
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives
Tyme Technologies shares jump premarket on news board to explore strategic options
Tyme Technologies, Inc.'s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript
TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET
Tyme Technologies Stock (TYME): Why The Price Fell
Source: https://incomestatements.info
Category: Stock Reports